2022-10-242022-10-242007-08Başkan, E. B. vd. (2007). "Open-label trial of cyclosporine for vulvar lichen sclerosus". Journal of the American Academy of Dermatology, 57(2), 276-278.0190-9622https://doi.org/10.1016/j.jaad.2007.03.006https://www.sciencedirect.com/science/article/pii/S0190962207005403http://hdl.handle.net/11452/29191Background: Lichen sclerosus (LS) is a chronic inflammatory disease of skin and mucosal surfaces which is generally difficult to treat. Objective: We evaluated the efficacy of oral cyclosporine in refractory vulvar LS. Methods: Five patients with refractory vulvar LS were treated with oral cyclosporine (3-4 mg/kg/d) for 3 months. They were followed up on a monthly basis. Results: At the end of the treatment, the mean total symptom score regressed significantly and clinical findings such as erythema and erosion showed marked improvement. Mild adverse effects were seen in 3 patients. Limitations: The patients did not give consent to rebiopsy at the end of the treatment. Conclusion: Moderate dose of oral cyclosporine could be an effective alternative in the treatment of refractory vulvar LS.eninfo:eu-repo/semantics/closedAccessDermatologyClobetasolAdministration, oralFollow-up studiesAdministration, topicalAgedAnti-inflammatory agentsClobetasolCyclosporineFemaleVulvar lichen sclerosusHumansMiddle agedOintmentsRetrospective studiesTreatment outcomeArticle0002483400000112-s2.0-3444725738927627857217442452DermatologyLichen Sclerosus Et Atrophicus; Vulva Kraurosis; Balanitis Xerotica ObliteransPimecrolimusCalcipotriolClobetasolCyclosporinEstrogenTestosteronePriority journalLichen sclerosus et atrophicusAdultAgedArticleClinical articleDrug dose reductionDrug efficacyErosionErythemaFemaleFollow upHumanRemissionOutcome assessmentOpen studyRetrospective studyTreatment durationTreatment response